fluconazole

• children reporting side effects, comparable agents

  unclear

  Side effects were reported by more patients treated with fluconazole (45 of 382; 11.8%) than by those patients treated with comparable agents (25 of 381; 6.6%)

  PMID:10428919 · one of two readings recorded this

• children reporting side effects, fluconazole

  increases

  Side effects were reported by more patients treated with fluconazole (45 of 382; 11.8%) than by those patients treated with comparable agents (25 of 381; 6.6%)

  PMID:10428919 · one of two readings recorded this

• children reporting treatment-related side effects

  unclear

  Overall, 58 (10.3%) children reported 80 treatment-related side effects.

  PMID:10428919 · one of two readings recorded this

• patients taking concomitant medications

  no effect

  Although 98.6% of patients were taking concomitant medications, no clinical or laboratory interactions were observed.

  PMID:10428919 · one of two readings recorded this

• treatment-related side effects and treatment-related laboratory abnormalities in children given fluconazole, pooled from 12 clinical studies; incidence in a single pooled arm, and fluconazole versus other antifungal agents in a five-study subset

  increases, side effects in 45 of 382 (11.8%) fluconazole patients versus 25 of 381 (6.6%) comparator patients

  Not recorded as a finding: the comparison was against another active treatment

  Side effects were reported by more patients treated with fluconazole (45 of 382; 11.8%) than by those patients treated with comparable agents (25 of 381; 6.6%); vomiting and diarrhea were the most common events in both groups.

  PMID:10428919 · one of two readings recorded this

• treatment-related side effects (patients reporting at least one) in children given fluconazole; controlled subset compared with other antifungal agents, mostly oral polyenes

  increases, side effects in 45 of 382 (11.8%) on fluconazole versus 25 of 381 (6.6%) on comparable agents

  Not recorded as a finding: the comparison was against another active treatment

  Side effects were reported by more patients treated with fluconazole (45 of 382; 11.8%) than by those patients treated with comparable agents (25 of 381; 6.6%); vomiting and diarrhea were the most common events in both groups.

  PMID:10428919 · one of two readings recorded this

• adverse events leading to cessation of the study drug

  no effect, p = 0.65

  the proportion of patients with adverse events leading to cessation of the study drug (RR = 0.75, 95% CI = 0.22–2.58, P = 0.65; I2 = 0%)

  PMID:16280069 · one of two readings recorded this

• candidaemia proportion (patients with candidaemia), pooled RR

  decreases, RR 0.21, 95% CI 0.06-0.72, p = 0.01

  Not recorded as a finding: no outcome node for candidaemia / invasive fungal infection incidence

  The use of prophylactic fluconazole was associated with a reduction in the proportion of patients with candidaemia (RR = 0.21, 95% CI = 0.06–0.72, P = 0.01; I2 = 0%) and fungal infections other than lower urinary tract infection (RR = 0.39, 95% CI = 0.24–0.65, P = 0.0003; I2 = 0%), but was associated with no significant difference in hospital mortality (RR = 0.82, 95% CI = 0.62–1.08, P = 0.15; I2 = 7%).

  PMID:16280069 · one of two readings recorded this

• fungal infections other than lower urinary tract infection

  decreases, p = 0.0003

  fungal infections other than lower urinary tract infection (RR = 0.39, 95% CI = 0.24–0.65, P = 0.0003; I2 = 0%)

  PMID:16280069 · one of two readings recorded this

• hospital mortality

  no effect, p = 0.15

  no significant difference in hospital mortality (RR = 0.82, 95% CI = 0.62–1.08, P = 0.15; I2 = 7%)

  PMID:16280069 · one of two readings recorded this

• patients colonised with or infected with fluconazole-resistant fungi

  no effect, p = 0.46

  The proportion of patients colonised with or infected with fluconazole-resistant fungi (RR = 0.66, 95% CI = 0.22–1.96, P = 0.46; I2 = 0%)

  PMID:16280069 · one of two readings recorded this

• patients requiring systemic amphotericin B as rescue therapy

  decreases, p = 0.004

  The proportion of patients requiring systemic amphotericin B as a rescue therapy for systemic fungal infection was lower after prophylactic use of fluconazole (RR = 0.35, 95% CI = 0.17–0.72, P = 0.004; I2 = 0%)

  PMID:16280069 · one of two readings recorded this

• proportion colonised with or infected with fluconazole-resistant fungi, pooled RR

  no effect, RR 0.66, 95% CI 0.22-1.96, p = 0.46

  Not recorded as a finding: no outcome node for antifungal-resistant colonisation/infection

  The proportion of patients colonised with or infected with fluconazole-resistant fungi (RR = 0.66, 95% CI = 0.22–1.96, P = 0.46; I2 = 0%) and the proportion of patients with adverse events leading to cessation of the study drug (RR = 0.75, 95% CI = 0.22–2.58, P = 0.65; I2 = 0%) were not different between the fluconazole group and the placebo group.

  PMID:16280069 · one of two readings recorded this

• proportion of patients requiring systemic amphotericin B as rescue therapy for systemic fungal infection

  decreases, RR = 0.35, 95% CI = 0.17–0.72, p = 0.004

  Not recorded as a finding: No outcome node for rescue antifungal therapy requirement.

  The proportion of patients requiring systemic amphotericin B as a rescue therapy for systemic fungal infection was lower after prophylactic use of fluconazole (RR = 0.35, 95% CI = 0.17–0.72, P = 0.004; I2 = 0%).

  PMID:16280069 · one of two readings recorded this

• proportion of patients with candidaemia, trial-reported

  decreases, RR = 0.21, 95% CI = 0.06–0.72, p = 0.01

  Not recorded as a finding: No outcome node for candidaemia incidence; nearest, infectious-complication-rate, requires each source's own case definition and a postoperative setting recorded, and candidaemia is a specific bloodstream infection.

  The use of prophylactic fluconazole was associated with a reduction in the proportion of patients with candidaemia (RR = 0.21, 95% CI = 0.06–0.72, P = 0.01; I2 = 0%) and fungal infections other than lower urinary tract infection (RR = 0.39, 95% CI = 0.24–0.65, P = 0.0003; I2 = 0%), but was associated with no significant difference in hospital mortality (RR = 0.82, 95% CI = 0.62–1.08, P = 0.15; I2 = 7%).

  PMID:16280069 · one of two readings recorded this

• proportion of patients with candidaemia

  decreases, p = 0.01

  a reduction in the proportion of patients with candidaemia (RR = 0.21, 95% CI = 0.06–0.72, P = 0.01; I2 = 0%)

  PMID:16280069 · one of two readings recorded this

• proportion requiring systemic amphotericin B rescue therapy for systemic fungal infection, pooled RR

  decreases, RR 0.35, 95% CI 0.17-0.72, p = 0.004

  Not recorded as a finding: no outcome node for prophylaxis failure requiring rescue antifungal therapy

  The proportion of patients requiring systemic amphotericin B as a rescue therapy for systemic fungal infection was lower after prophylactic use of fluconazole (RR = 0.35, 95% CI = 0.17–0.72, P = 0.004; I2 = 0%).

  PMID:16280069 · one of two readings recorded this

• total length of hospital stay

  no effect, p = 0.94

  The total length of hospital stay was no different between the fluconazole group and the placebo group (weight mean difference = -0.4 days, 95% CI = -10.35 to 9.54, P = 0.94; I2 = 52.4%)

  PMID:16280069 · one of two readings recorded this

• adverse events leading to antifungal prophylaxis discontinuation or modification

  increases

  fluconazole prophylaxis (RR 1.95, 95% CI 1.24–3.07)

  PMID:22568999 · one of two readings recorded this

• IFI-related mortality

  decreases

  mortality (RR 0.67, 95% CI 0.47–0.96)

  PMID:22568999 · one of two readings recorded this

• invasive aspergillosis (IA)

  decreases

  the risk of IA (RR 0.53, 95% CI 0.37–0.75)

  PMID:22568999 · one of two readings recorded this

• overall mortality

  no effect

  overall mortality (RR 1.0, 95% CI 0.88–1.13)

  PMID:22568999 · one of two readings recorded this

• proven or probable IFI, sensitivity analysis

  unclear

  with the exception of proven or probably IFI which was no longer significant after removing the three studies that used oral itraconazole solution doses

  PMID:22568999 · one of two readings recorded this

• proven or probable invasive fungal infection (IFI)

  decreases, p = 0.03

  reduced the risk of IFI (RR 0.71, 95% CI 0.52–0.98; P=0.03)

  PMID:22568999 · one of two readings recorded this

• proven or probable invasive fungal infection, invasive aspergillosis, IFI-related mortality, overall mortality (3-month observation) and adverse events leading to discontinuation, mould-active versus fluconazole prophylaxis

  no effect, RR 1.0, 95% CI 0.88–1.13

  Not recorded as a finding: the comparison was against another active treatment

  Importantly, mould-active prophylaxis did not significantly influence overall mortality (RR 1.0, 95% CI 0.88–1.13).

  PMID:22568999 · one of two readings recorded this

• proven or probable invasive fungal infection, mould-active versus fluconazole prophylaxis, pooled RR across 18 trials; overall mortality at 3 months

  no effect, overall mortality RR 1.0, 95% CI 0.88-1.13 (mould-active versus fluconazole); fluconazole is the active comparator, not the exposure

  Not recorded as a finding: the comparison was against another active treatment

  Importantly, mould-active prophylaxis did not significantly influence overall mortality (RR 1.0, 95% CI 0.88–1.13).

  PMID:22568999 · one of two readings recorded this

• all adverse events

  no effect, p = 0.238

  The relative risk of all AEs in the fluconazole group was not statistically different from those treated with placebo (RR 1.30, 95 % CI 0.84–2.03, P = 0.238)

  PMID:23325436 · one of two readings recorded this

• all adverse events

  no effect, p = 0.85

  Compared to all other antifungal drugs there was again no significant increase in the risk (RR 1.05, 95 % CI 0.62–1.80, P = 0.85)

  PMID:23325436 · one of two readings recorded this

• all adverse events

  no effect, p = 0.364

  or the prophylaxis group (RR 1.68, 95 % CI 0.55–5.11, P = 0.364)

  PMID:23325436 · one of two readings recorded this

• all adverse events

  no effect, p = 0.437

  The overall relative risk of adverse events in the fluconazole group was not significantly different within the treatment group (RR 0.82, 95 % CI 0.49–1.36, P = 0.437)

  PMID:23325436 · one of two readings recorded this

• cholestasis in extremely low birth weight neonates, fluconazole-exposed

  increases, p = 0.001

  Another prophylactic cohort study recorded 60 cases of cholestasis in 140 fluconazole-exposed extremely low birth weight neonates as against 12 in 137 non-exposed neonates (P < 0.001)

  PMID:23325436 · one of two readings recorded this

• cholestasis in extremely low birth weight neonates, single cohort without unexposed group

  unclear

  one of which was a prophylactic study which recorded 127 cases of cholestasis in 409 fluconazole-exposed extremely low birth weight neonates

  PMID:23325436 · one of two readings recorded this

• gastrointestinal adverse events incidence by dose

  no effect, p = 0.585

  dose (IRR 1.07, 95 % CI 0.85–1.39, P = 0.585)

  PMID:23325436 · one of two readings recorded this

• gastrointestinal adverse events incidence by duration of treatment

  no effect, p = 0.07

  duration of treatment (IRR 1.01, 95 % CI 0.99–1.03, P = 0.07)

  PMID:23325436 · one of two readings recorded this

• gastrointestinal adverse events incidence, neonates vs children

  decreases, p = 0.012

  the incidence of GI AEs were lower in neonates than children (IRR 0.15, 95 % CI 0.03–0.66, p = 0.012)

  PMID:23325436 · one of two readings recorded this

• gastrointestinal adverse events incidence, oral administration

  no effect, p = 0.125

  Although oral administration increased the incidence of GI AEs, this increase was not significant (IRR 3.22, 95 % CI 0.72–14.33, P = 0.125)

  PMID:23325436 · one of two readings recorded this

• gastrointestinal events versus placebo, pooled RR

  no effect, RR 0.81, 95% CI 0.12-5.60, p = 0.831

  Not recorded as a finding: no outcome node for gastrointestinal adverse events as a distinct endpoint

  There was no statistical difference in the risk of GI events of fluconazole compared with placebo (RR 0.81, 95 %CI 0.12–5.60, P = 0.831).

  PMID:23325436 · one of two readings recorded this

• gastrointestinal events

  no effect, p = 0.831

  GI events | 0.81 | 0.12–5.59 | 0.831

  PMID:23325436 · one of two readings recorded this

• gastrointestinal events

  no effect, p = 0.219

  GI events | 2.02 | 0.66–6.23 | 0.219

  PMID:23325436 · one of two readings recorded this

• gastrointestinal events

  no effect, p = 0.235

  GI events | 1.23 | 0.88–1.71 | 0.235

  PMID:23325436 · one of two readings recorded this

• hepatotoxicity incidence by dose

  decreases, p = 0.001

  The incidence of hepatotoxicity appears to decrease with increasing dose (IRR 0.52, 95 % CI 0.37–0.74, P = 0.001)

  PMID:23325436 · one of two readings recorded this

• hepatotoxicity incidence, neonates vs children

  no effect

  Although the incidence of hepatotoxicity in neonates on fluconazole was greater than that in children (IRR 1.33, 95 % CI 0.63–2.80)

  PMID:23325436 · one of two readings recorded this

• hepatotoxicity incidence, oral vs IV

  decreases, p = 0.001

  Patients on oral fluconazole were less likely to have hepatotoxicity than those on IV fluconazole (IRR 0.21, 95 % CI 0.92–0.47, P = 0.001)

  PMID:23325436 · one of two readings recorded this

• hepatotoxicity incidence, therapeutic vs prophylactic use

  increases, p = 0.001

  the incidence of hepatotoxicity with therapeutic fluconazole was significantly greater than that with prophylaxis (IRR 5.34 95 % CI 1.99–14.37, P = 0.001)

  PMID:23325436 · one of two readings recorded this

• hepatotoxicity (undefined in the review) versus placebo and versus other antifungals, pooled RR

  no effect, RR 1.36 (95% CI 0.87-2.14) versus placebo; RR 1.43 (95% CI 0.67-3.03) versus other antifungals

  Not recorded as a finding: node hepatotoxicity-incidence requires an adjudicated transaminase or bilirubin threshold; the review states no definition, and the sentence mixes two comparators

  The relative risk of hepatotoxicity with fluconazole was 1.36 (95 % CI 0.87–2.14) and 1.43 (95 % CI 0.67–3.03) when compared with placebo and other antifungals, respectively (Fig. and); these relationships were not statistically significant (P = 0.175 and 0.352, respectively).

  PMID:23325436 · one of two readings recorded this

• hepatotoxicity

  no effect, p = 0.175

  Hepatotoxicity | 1.37 | 0.87–2.14 | 0.175

  PMID:23325436 · one of two readings recorded this

• hepatotoxicity

  increases, p = 0.016

  Hepatotoxicity | 1.92 | 1.13–3.26 | 0.016*

  PMID:23325436 · one of two readings recorded this

• hepatotoxicity

  no effect, p = 0.352

  Hepatotoxicity | 1.43 | 0.67–3.03 | 0.352

  PMID:23325436 · one of two readings recorded this

• mortality, fluconazole versus placebo, pooled paediatric trials; also hepatotoxicity and gastrointestinal events as relative risks versus placebo and versus other antifungals

  RR 0.62, 95 % CI, 0.38–1.03, p = 0.067

  Not recorded as a finding: a direction is stated and the estimate does not support it

  There was a decrease in mortality when fluconazole was compared with placebo, but this was not significant (RR 0.62, 95 % CI, 0.38–1.03, P = 0.067).

  PMID:23325436 · one of two readings recorded this

• mortality, fluconazole versus placebo, pooled RR in paediatric patients

  decreases, RR 0.62, 95% CI 0.38-1.03, p = 0.067

  Not recorded as a finding: sentence states a decrease but not significant (RR 0.62, p 0.067) with no two-sided null statement; direction_stated_but_not_significant

  There was a decrease in mortality when fluconazole was compared with placebo, but this was not significant (RR 0.62, 95 % CI, 0.38–1.03, P = 0.067).

  PMID:23325436 · one of two readings recorded this

• mortality

  no effect, p = 0.067

  Mortality | 0.62 | 0.37–1.03 | 0.067

  PMID:23325436 · one of two readings recorded this

• mortality

  no effect, p = 0.825

  Mortality | 1.01 | 0.02–50.41 | 0.825

  PMID:23325436 · one of two readings recorded this

• mortality

  no effect, p = 0.96

  Mortality | 1.01 | 0.72–1.41 | 0.960

  PMID:23325436 · one of two readings recorded this

• resolution of hepatotoxicity symptoms among patients with complete follow-up

  unclear

  Therefore, 84 % of patients, for whom follow-up was complete, had resolution of symptoms

  PMID:23325436 · one of two readings recorded this

• withdrawal due to adverse event

  no effect, p = 0.828

  Withdrawal due to AE | 0.78 | 0.08–7.24 | 0.828

  PMID:23325436 · one of two readings recorded this

• withdrawal due to adverse event

  no effect, p = 0.992

  Withdrawal due to AE | 1.01 | 1.11–9.59 | 0.992

  PMID:23325436 · one of two readings recorded this

• withdrawal due to adverse event

  no effect, p = 0.534

  Withdrawal due to AE | 1.25 | 0.62–2.53 | 0.534

  PMID:23325436 · one of two readings recorded this

• withdrawals due to elevated liver enzymes among drug-related withdrawals

  unclear

  Of the 41 drug-related withdrawals,17 (42 %) were due to elevated liver enzymes

  PMID:23325436 · one of two readings recorded this

• duration of treatment on trial drugs

  unclear, n = 391

  (77 days with voriconazole versus 10 days with amphotericin B)

  PMID:24563222 · one of two readings recorded this

• fungal-free survival and invasive fungal infections at 180 days, voriconazole versus fluconazole prophylaxis after allogeneic stem cell transplantation (one trial of three)

  no effect, no difference in fungal free survival or invasive fungal infections between voriconazole and fluconazole

  Not recorded as a finding: the comparison was against another active treatment

  The third trial failed to find a difference in fungal free survival or invasive fungal infections at 180 days when voriconazole was compared to fluconazole.

  PMID:24563222 · one of two readings recorded this

• fungal-free survival and invasive fungal infections at 180 days, voriconazole versus fluconazole prophylaxis after allogeneic stem cell transplantation

  no effect

  Not recorded as a finding: the comparison was against another active treatment

  The third trial failed to find a difference in fungal free survival or invasive fungal infections at 180 days when voriconazole was compared to fluconazole.

  PMID:24563222 · one of two readings recorded this

• fungal free survival and invasive fungal infections at 180 days

  no effect, n = 600

  The third trial failed to find a difference in fungal free survival or invasive fungal infections at 180 days when voriconazole was compared to fluconazole.

  PMID:24563222 · one of two readings recorded this

• mortality

  increases, n = 849

  More patients died in the voriconazole group

  PMID:24563222 · one of two readings recorded this

• morbidity and mortality (deaths, fungal infection) in neutropenic cancer patients, fluconazole versus amphotericin B, pooled across 17 trials

  no effect, no significant differences in effect between fluconazole and amphotericin B, wide confidence intervals

  Not recorded as a finding: the comparison was against another active treatment

  There were no significant differences in effect between fluconazole and amphotericin B, but the confidence intervals were wide.

  PMID:25188769 · one of two readings recorded this

• morbidity and mortality (fungal infection, deaths, drop-outs, adverse effects) in neutropenic cancer patients, fluconazole versus amphotericin B

  no effect

  Not recorded as a finding: the comparison was against another active treatment

  There were no significant differences in effect between fluconazole and amphotericin B, but the confidence intervals were wide.

  PMID:25188769 · one of two readings recorded this

• morbidity and mortality (overall effect of fluconazole vs amphotericin B)

  no effect, n = 3798

  There were no significant differences in effect between fluconazole and amphotericin B, but the confidence intervals were wide.

  PMID:25188769 · one of two readings recorded this

• study dropout

  increases

  More patients dropped out of the study when they received amphotericin B, but as none of the trials were blinded decisions on premature interruption of therapy could have been biased.

  PMID:25188769 · one of two readings recorded this

• all-cause deaths, posaconazole vs placebo, fluconazole, and itraconazole solution

  decreases, OR 0.49-0.54 (95% CI 0.28-0.88) favoring posaconazole

  Posaconazole significantly reduced all-cause deaths, compared to placebo, fluconazole, and itraconazole solution (OR, 0.49 to 0.54 [95% CI, 0.28 to 0.88]).

  PMID:26525782 · one of two readings recorded this

• all-cause deaths

  decreases, OR 0.49 to 0.54 (95% CI 0.28-0.88), posaconazole vs placebo, fluconazole, and itraconazole solution

  Posaconazole significantly reduced all-cause deaths, compared to placebo, fluconazole, and itraconazole solution (OR, 0.49 to 0.54 [95% CI, 0.28 to 0.88]).

  PMID:26525782 · one of two readings recorded this

• incidence of invasive fungal infections and all-cause deaths in patients receiving triazole antifungal prophylaxis (fluconazole, itraconazole, posaconazole, voriconazole), network meta-analysis

  OR 0.35 (95% CI 0.16-0.73) posaconazole vs fluconazole for IFI incidence, n = 5505

  Not recorded as a finding: the comparison was against another active treatment

  Posaconazole was better than fluconazole (odds ratio [OR], 0.35 [95% confidence interval [CI], 0.16 to 0.73]) and itraconazole capsule (OR, 0.25 [95% CI, 0.06 to 0.97]), but not voriconazole (OR, 1.31 [95% CI, 0.43 to 4.01]), in preventing IFIs.

  PMID:26525782 · one of two readings recorded this

• incidence of invasive fungal infections, posaconazole vs fluconazole

  decreases, OR 0.35 (95% CI 0.16-0.73) favoring posaconazole

  Posaconazole was better than fluconazole (odds ratio [OR], 0.35 [95% confidence interval [CI], 0.16 to 0.73]) and itraconazole capsule (OR, 0.25 [95% CI, 0.06 to 0.97]), but not voriconazole (OR, 1.31 [95% CI, 0.43 to 4.01]), in preventing IFIs.

  PMID:26525782 · one of two readings recorded this

• incidence of invasive fungal infections

  decreases, OR 0.35 (95% CI 0.16-0.73), posaconazole vs fluconazole

  Posaconazole was better than fluconazole (odds ratio [OR], 0.35 [95% confidence interval [CI], 0.16 to 0.73]) and itraconazole capsule (OR, 0.25 [95% CI, 0.06 to 0.97]), but not voriconazole (OR, 1.31 [95% CI, 0.43 to 4.01]), in preventing IFIs.

  PMID:26525782 · one of two readings recorded this

• clinical and laboratory adverse event incidence

  no effect

  The incidence of clinical and laboratory adverse events was similar for infants who received fluconazole compared with placebo.

  PMID:27298330 · one of two readings recorded this

• clinical and laboratory adverse events

  no effect

  The incidence of clinical and laboratory adverse events was similar for infants who received fluconazole compared with placebo.

  PMID:27298330 · one of two readings recorded this

• fluconazole resistance among tested isolates

  no effect

  There was no statistically significant difference in the proportion of tested isolates that were resistant to fluconazole between the fluconazole and placebo groups.

  PMID:27298330 · one of two readings recorded this

• proportion of tested isolates resistant to fluconazole

  no effect

  There was no statistically significant difference in the proportion of tested isolates that were resistant to fluconazole between the fluconazole and placebo groups.

  PMID:27298330 · one of two readings recorded this

• effect of fluconazole dose on relative risk of invasive fungal infection

  no effect

  Not recorded as a finding: no outcome node for invasive fungal infection incidence; dose-comparison sensitivity finding

  The fluconazole dose had no significant impact on the RR of invasive fungal infections.

  PMID:27350534 · one of two readings recorded this

• invasive fungal infection incidence by fluconazole dose

  no effect

  The fluconazole dose had no significant impact on the RR of invasive fungal infections.

  PMID:27350534 · one of two readings recorded this

• invasive fungal infection risk ratio by fluconazole dose

  no effect

  The fluconazole dose had no significant impact on the RR of invasive fungal infections.

  PMID:27350534 · one of two readings recorded this

• mortality, prophylactic fluconazole vs no prophylaxis

  no effect, RR 0.82 (95% CI 0.60-1.12), p = 0.2093

  The RR of mortality presented no significant differences between prophylactic fluconazole and no prophylaxis (RR 0.82, 95 % CI 0.60 to 1.12, p = 0.2093).

  PMID:27350534 · one of two readings recorded this

• mortality

  no effect, RR 0.82 (95% CI 0.60-1.12), p = 0.2093

  The RR of mortality presented no significant differences between prophylactic fluconazole and no prophylaxis (RR 0.82, 95 % CI 0.60 to 1.12, p = 0.2093).

  PMID:27350534 · both readings recorded this

• adverse reaction occurrence

  no effect

  Our research indicated that the application of fluconazole did not result in intolerable adverse reactions in patients.

  PMID:37106436 · one of two readings recorded this

• adverse reactions to fluconazole in VLBW infants

  no effect

  Our research indicated that the application of fluconazole did not result in intolerable adverse reactions in patients.

  PMID:37106436 · one of two readings recorded this

• incidence of invasive fungal infection, fungal colonization rate, and mortality in very low birth weight infants receiving fluconazole prophylaxis

  decreases

  Not recorded as a finding: no estimate is reported anywhere

  Fluconazole is effective in preventing invasive fungal infections in very low birth weight infants without serious adverse effects.

  PMID:37106436 · one of two readings recorded this

• incidence of invasive fungal infections, fungal colonization rate, and mortality, in very low birth weight infants given fluconazole prophylaxis

  decreases

  Not recorded as a finding: no estimate is reported anywhere

  Fluconazole is effective in preventing invasive fungal infections in very low birth weight infants without serious adverse effects.

  PMID:37106436 · one of two readings recorded this

• incidence of invasive fungal infections

  decreases

  Fluconazole is effective in preventing invasive fungal infections in very low birth weight infants without serious adverse effects.

  PMID:37106436 · one of two readings recorded this

• invasive fungal infection incidence in VLBW infants

  decreases

  Fluconazole is effective in preventing invasive fungal infections in very low birth weight infants without serious adverse effects.

  PMID:37106436 · one of two readings recorded this

• Age, median (IQR)

  no effect, p = 0.566

  Age | 40 (35-48) | 45 (38-52) | 45 (38-48) | 0.566

  PMID:39632750 · one of two readings recorded this

• Candida species isolated: C. albicans + C. glabrata

  decreases

  C.albicans + C.glabrata | 2 | 0 | 3 | 0 | 7 | 0 | 12 | 0

  PMID:39632750 · one of two readings recorded this

• Candida species isolated: C. albicans + C. krusei + C. glabrata

  decreases

  C.albicans + C.krusei+ C.glabrata | 1 | 0 | 4 | 0 | 4 | 0 | 9 | 0

  PMID:39632750 · one of two readings recorded this

• Candida species isolated: C. albicans + C. krusei

  C.albican + C.krusei | 1 | 0 | 1 | 1 | 3 | 0 | 5 | 1

  PMID:39632750 · one of two readings recorded this

• Candida species isolated: C. albicans + C. tropicalis

  C.albicans + C.tropicalis | 1 | 0 | 1 | 0 | 0 | 0 | 2 | 0

  PMID:39632750 · one of two readings recorded this

• Candida species isolated: C. albicans

  decreases

  C.albicans | 11 | 1 | 8 | 1 | 5 | 2 | 24 | 4

  PMID:39632750 · one of two readings recorded this

• Candida species isolated: C. glabrata

  C.glabrata | 0 | 1 | 0 | 7 | 0 | 3 | 0 | 0

  PMID:39632750 · one of two readings recorded this

• Candida species isolated: C. krusei + C. glabrata

  C.krusei + C.glabrata | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 2

  PMID:39632750 · one of two readings recorded this

• Candida species isolated: C. krusei

  C.krusei | 1 | 1 | 0 | 1 | 0 | 5 | 1 | 7

  PMID:39632750 · one of two readings recorded this

• Candida species isolated: C. tropicalis

  C.tropicalis | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 2

  PMID:39632750 · one of two readings recorded this

• Candida species isolated: no organism

  No organism | 0 | 1 | 0 | 7 | 0 | 6 | 0 | 14

  PMID:39632750 · one of two readings recorded this

• Candida species isolated: total

  Total | 18 | 5 | 18 | 18 | 19 | 18 | 55 | 41

  PMID:39632750 · one of two readings recorded this

• CD4 count, median (IQR)

  no effect, p = 0.59

  CD4 | 300 (250-345) | 311 (236-355) | 245 (212-370) | 0.590

  PMID:39632750 · one of two readings recorded this

• Clinical resolution

  Out of 18 patients in Group A 70.58% of the patients had clinical resolution and 72% of the patients had mycological eradication

  PMID:39632750 · one of two readings recorded this

• Clinical resolution

  Out of 18 patients in Group B 47% of the patients had clinical resolution and 52% of the patients had mycological eradication

  PMID:39632750 · one of two readings recorded this

• Clinical resolution

  Out of 19 patients in Group C 27% of the patients has clinical resolution and 47.36% of the patients had mycological eradication

  PMID:39632750 · one of two readings recorded this

• Clinical signs (Physicians Assessment Scale), before vs after treatment

  decreases, p = 0.001

  Group A (Fluconazole mucoadhesive film) N = 18 | 2.0 (2-3) | 0.0 (0-1) | <0.001

  PMID:39632750 · one of two readings recorded this

• Clinical signs (Physicians Assessment Scale), before vs after treatment

  decreases, p = 0.001

  Group B (Fluconazole tablet) N = 18 | 3.0 (2-3) | 1.0 (0-1) | <0.001

  PMID:39632750 · one of two readings recorded this

• Clinical signs (Physicians Assessment Scale), before vs after treatment

  decreases, p = 0.001

  Group C (Fluconazole mouth rinse) N = 19 | 2.0 (2-3) | 1.0 (1-1) | <0.001

  PMID:39632750 · one of two readings recorded this

• Clinical symptoms severity score, before vs after treatment

  decreases, p = 0.001

  Group A (Fluconazole mucoadhesive film) N = 18 | 2.0 (2-3) | 0.0 (0-0) | <0.001

  PMID:39632750 · one of two readings recorded this

• Clinical symptoms severity score, before vs after treatment

  decreases, p = 0.001

  Group B (Fluconazole tablet) N = 18 | 2.5 (2-3) | 0.0 (0-1) | <0.001

  PMID:39632750 · one of two readings recorded this

• Clinical symptoms severity score, before vs after treatment

  decreases, p = 0.001

  Group C (Fluconazole mouth rinse) N = 19 | 2.0 (2-2) | 1.0 (1-1) | <0.001

  PMID:39632750 · one of two readings recorded this

• Colony count, before vs after treatment

  decreases, p = 0.001

  Group A (Fluconazole mucoadhesive film) N = 18 | 1825 | 23.44 | <0.001

  PMID:39632750 · one of two readings recorded this

• Colony count, before vs after treatment

  decreases, p = 0.001

  Group B (Fluconazole tablet) N = 18 | 1727.78 | 133.82 | <0.001

  PMID:39632750 · one of two readings recorded this

• Colony count, before vs after treatment

  decreases, p = 0.001

  Group C (Fluconazole mouth rinse) N = 19 | 1896.84 | 226.28 | <0.001

  PMID:39632750 · one of two readings recorded this

• Improvement in clinical signs, between-group comparison

  modulates, p = 0.001

  A significant difference was observed in the improvement of clinical signs between the groups (KW = 14.203; P < 0.001)

  PMID:39632750 · one of two readings recorded this

• Improvement in clinical signs, pairwise

  no effect, p = 0.754

  there were no significant differences between groups A and B (P = 0.754)

  PMID:39632750 · one of two readings recorded this

• Improvement in clinical signs, pairwise

  increases, p = 0.001

  groups A and B had a greater improvement compared to group C (P = 0.001 and P = 0.005, respectively)

  PMID:39632750 · one of two readings recorded this

• Improvement in clinical signs, pairwise

  increases, p = 0.005

  groups A and B had a greater improvement compared to group C (P = 0.001 and P = 0.005, respectively)

  PMID:39632750 · one of two readings recorded this

• Improvement in clinical symptoms, between-group comparison

  modulates, p = 0.001

  There was a significant difference in the magnitude of improvement in symptoms between the groups (KW = 18.90; P < 0.001)

  PMID:39632750 · one of two readings recorded this

• Improvement in clinical symptoms, pairwise

  no effect, p = 0.247

  There were no significant differences in the improvement of symptoms between groups A and B (P = 0.247)

  PMID:39632750 · one of two readings recorded this

• Improvement in clinical symptoms, pairwise

  increases, p = 0.001

  patients in group A and group B had a greater improvement in symptoms compared to group C (P < 0.001 and P = 0.002, respectively)

  PMID:39632750 · one of two readings recorded this

• Improvement in clinical symptoms, pairwise

  increases, p = 0.002

  patients in group A and group B had a greater improvement in symptoms compared to group C (P < 0.001 and P = 0.002, respectively)

  PMID:39632750 · one of two readings recorded this

• Improvement in colony count, between-group comparison

  no effect, p = 0.149

  There was no overall difference in the magnitude of improvement of colony count between the groups (KW = 3.804; P = 0.149)

  PMID:39632750 · one of two readings recorded this

• Improvement in oral discomfort (VAS), between-group comparison

  modulates, p = 0.003

  A significant difference in VAS scores was observed between the groups (KW = 11.585; P = 0.003)

  PMID:39632750 · one of two readings recorded this

• Improvement in oral discomfort (VAS), pairwise

  increases, p = 0.005

  patients in group A experienced a greater improvement in oral discomfort compared to group B (P = 0.005) and group C (P = 0.002)

  PMID:39632750 · one of two readings recorded this

• Improvement in oral discomfort (VAS), pairwise

  increases, p = 0.002

  patients in group A experienced a greater improvement in oral discomfort compared to group B (P = 0.005) and group C (P = 0.002)

  PMID:39632750 · one of two readings recorded this

• Male participants

  no effect, p = 0.699

  Male | 10 (55.6%) | 11 (61.1%) | 9 (47.4%) | 0.699

  PMID:39632750 · one of two readings recorded this

• Mycological cure

  Mycological cure was observed in 72%, 52.94%, and 47.36% patients in groups A, B and C, respectively

  PMID:39632750 · one of two readings recorded this

• Mycological eradication

  Out of 18 patients in Group A 70.58% of the patients had clinical resolution and 72% of the patients had mycological eradication

  PMID:39632750 · one of two readings recorded this

• Mycological eradication

  Out of 18 patients in Group B 47% of the patients had clinical resolution and 52% of the patients had mycological eradication

  PMID:39632750 · one of two readings recorded this

• Mycological eradication

  Out of 19 patients in Group C 27% of the patients has clinical resolution and 47.36% of the patients had mycological eradication

  PMID:39632750 · one of two readings recorded this

• oral discomfort on a visual analogue scale, clinical symptom severity score, clinical signs on the Physicians Assessment Scale, Candida colony count and mycological cure in HIV-related oral candidiasis, fluconazole mucoadhesive film versus fluconazole tablet versus fluconazole mouth rinse

  KW = 11.585 across groups; group A greater improvement in oral discomfort than group B (P = 0.005) and group C (P = 0.002), p = 0.003

  Not recorded as a finding: the comparison was against another active treatment

  A significant difference in VAS scores was observed between the groups (KW = 11.585; P = 0.003); patients in group A experienced a greater improvement in oral discomfort compared to group B (P = 0.005) and group C (P = 0.002).

  PMID:39632750 · one of two readings recorded this

• oral discomfort on a visual analogue scale in HIV-related oral candidiasis, fluconazole mucoadhesive film versus fluconazole 100 mg tablet versus fluconazole mouth rinse

  greater improvement in oral discomfort with film than tablet (P = 0.005) or mouth rinse (P = 0.002)

  Not recorded as a finding: the comparison was against another active treatment

  A significant difference in VAS scores was observed between the groups (KW = 11.585; P = 0.003); patients in group A experienced a greater improvement in oral discomfort compared to group B (P = 0.005) and group C (P = 0.002).

  PMID:39632750 · one of two readings recorded this

• Visual analogue scale score for oral discomfort, before vs after treatment

  decreases, p = 0.0001

  Group A (Fluconazole mucoadhesive film) N = 18 | 7 (5.75-8) | 0 (0-1) | <0.0001

  PMID:39632750 · one of two readings recorded this

• Visual analogue scale score for oral discomfort, before vs after treatment

  decreases, p = 0.0001

  Group B (Fluconazole tablet) N = 18 | 7 (5.75-8) | 1 (0-3) | <0.0001

  PMID:39632750 · one of two readings recorded this

• Visual analogue scale score for oral discomfort, before vs after treatment

  decreases, p = 0.0001

  Group C (Fluconazole mouth rinse) N = 19 | 7 (6-8) | 2 (0-3) | <0.0001

  PMID:39632750 · one of two readings recorded this

• Age (years), mean ± SD

  Mean ± SD | 53.62 ± 1.55 | 54.17 ± 1.89

  PMID:39651788 · one of two readings recorded this

• C. albicans positive cultures

  C. albicans (n) | 22 | 16

  PMID:39651788 · one of two readings recorded this

• C. albicans positive cultures

  C. albicans (n) | 12 | 20

  PMID:39651788 · one of two readings recorded this

• C. albicans positive cultures

  C. albicans (n) | 8 | 18

  PMID:39651788 · one of two readings recorded this

• C. glabrata positive cultures

  C. glabrata (n) | 2 | 2

  PMID:39651788 · one of two readings recorded this

• C. glabrata positive cultures

  C. glabrata (n) | 0 | 3

  PMID:39651788 · one of two readings recorded this

• C. glabrata positive cultures

  C. glabrata (n) | 1 | 3

  PMID:39651788 · one of two readings recorded this

• C. krusei positive cultures

  C. krusei (n) | 1 | 3

  PMID:39651788 · one of two readings recorded this

• C. krusei positive cultures

  C. krusei (n) | 2 | 1

  PMID:39651788 · one of two readings recorded this

• C. krusei positive cultures

  C. krusei (n) | 5 | 2

  PMID:39651788 · one of two readings recorded this

• C. parapsilosis positive cultures

  C. parapsilosis (n) | 1 | 1

  PMID:39651788 · one of two readings recorded this

• C. parapsilosis positive cultures

  C. parapsilosis (n) | 1 | 0

  PMID:39651788 · one of two readings recorded this

• C. parapsilosis positive cultures

  C. parapsilosis (n) | 0 | 0

  PMID:39651788 · one of two readings recorded this

• C. tropicalis positive cultures

  C. tropicalis (n) | 2 | 5

  PMID:39651788 · one of two readings recorded this

• C. tropicalis positive cultures

  C. tropicalis (n) | 0 | 6

  PMID:39651788 · one of two readings recorded this

• C. tropicalis positive cultures

  C. tropicalis (n) | 1 | 7

  PMID:39651788 · one of two readings recorded this

• Clinical oral candidiasis

  no effect, n = 78

  Clinical oral candidiasis occurred in 3 out of 78 patients—1 in Arm A and 2 in Arm B

  PMID:39651788 · one of two readings recorded this

• Grade 1 mucositis patients

  with 20 patients (54.05%) in each arm exhibiting grade 1 mucositis

  PMID:39651788 · one of two readings recorded this

• Grade 1 mucositis patients

  most patients in Arm A (22 patients, 61.11%) and Arm B (19 patients, 52.78%) had grade 1 mucositis

  PMID:39651788 · one of two readings recorded this

• Grade 2 mucositis patients

  Grade 2 mucositis occurred in 8 patients (21.62%) in Arm A and 9 patients (24.32%) in Arm B

  PMID:39651788 · one of two readings recorded this

• Grade 2 mucositis patients

  grade 2 mucositis was observed in 9 patients (25%) in Arm A and 15 patients (41.67%) in Arm B

  PMID:39651788 · one of two readings recorded this

• Grade 2 RIOM incidence, adjusted OR (adjusted for cancer diagnosis)

  no effect, p = 0.365

  After adjusting for cancer diagnosis, the aOR was 0.577 (95% CI: 0.175–1.898, p = 0.365)

  PMID:39651788 · one of two readings recorded this

• Grade 2 RIOM incidence, adjusted OR (adjusted for cancer diagnosis)

  decreases, p = 0.039

  After adjusting for cancer diagnosis, the aOR was 0.294 (95% CI: 0.092–0.937, p = 0.039)

  PMID:39651788 · one of two readings recorded this

• Grade 2 RIOM incidence, unadjusted OR

  no effect, p = 0.782

  By week 4, the OR for grade 2 toxicity incidence between the two arms was 0.858 (95% CI: 0.290–2.539, p = 0.782)

  PMID:39651788 · one of two readings recorded this

• Grade 2 RIOM incidence, unadjusted OR

  no effect, p = 0.137

  By week 7, the OR for Grade 2 toxicity was 0.467 (95% CI: 0.171–1.274, p = 0.137)

  PMID:39651788 · one of two readings recorded this

• Mean percentage of weight loss

  The mean percentage of weight loss was 6.20% in Arm A and 6.79% in Arm B

  PMID:39651788 · one of two readings recorded this

• Median Candida CFUs, between-arm difference

  decreases, p = 0.05

  The difference in median CFUs between the two arms was statistically significant by week 7 (p = 0.050)

  PMID:39651788 · one of two readings recorded this

• Median Candida CFUs

  In Arm A, the median CFUs were high at 180 (IQR: 1.7–8550) in week 1 but then dropped to 20 (IQR: 0–1106.7) in week 4 and 0 (IQR: 0–5780.8) in week 7

  PMID:39651788 · one of two readings recorded this

• Median Candida CFUs

  In Arm A, the median CFUs were high at 180 (IQR: 1.7–8550) in week 1 but then dropped to 20 (IQR: 0–1106.7) in week 4 and 0 (IQR: 0–5780.8) in week 7

  PMID:39651788 · one of two readings recorded this

• Median Candida CFUs

  In Arm A, the median CFUs were high at 180 (IQR: 1.7–8550) in week 1 but then dropped to 20 (IQR: 0–1106.7) in week 4 and 0 (IQR: 0–5780.8) in week 7

  PMID:39651788 · one of two readings recorded this

• Median Candida CFUs

  Arm B started with low CFUs at 18.3 (IQR: 0–580) in week 1, increased to 456.7 (IQR: 6.7–16 000) by week 4, and further rose to 3650 (IQR: 0–40983.3) in week 7

  PMID:39651788 · one of two readings recorded this

• Median Candida CFUs

  Arm B started with low CFUs at 18.3 (IQR: 0–580) in week 1, increased to 456.7 (IQR: 6.7–16 000) by week 4, and further rose to 3650 (IQR: 0–40983.3) in week 7

  PMID:39651788 · one of two readings recorded this

• Median Candida CFUs

  Arm B started with low CFUs at 18.3 (IQR: 0–580) in week 1, increased to 456.7 (IQR: 6.7–16 000) by week 4, and further rose to 3650 (IQR: 0–40983.3) in week 7

  PMID:39651788 · one of two readings recorded this

• Median overall treatment time

  the median overall treatment time (OTT) was 50 days (interquartile range [IQR] 47–58.25) in Arm A and 51 days (IQR 47.75–57) in Arm B

  PMID:39651788 · one of two readings recorded this

• No Candida growth

  No growth (%) | 9 (23.1) | 13 (33.3)

  PMID:39651788 · one of two readings recorded this

• No Candida growth

  No growth (%) | 15 (40.5) | 6 (16.2)

  PMID:39651788 · one of two readings recorded this

• No Candida growth

  No growth (%) | 20 (55.6) | 10 (27.8)

  PMID:39651788 · one of two readings recorded this

• Oral dose (Gy), mean ± SD

  Mean ± SD | 53.70 ± 6.63 | 52.29 ± 7.68

  PMID:39651788 · one of two readings recorded this

• Overall treatment time, between-arm difference

  no effect, p = 0.697

  no significant differences in OTT or median weight loss between the two arms (p = 0.697 and p = 0.734, respectively)

  PMID:39651788 · one of two readings recorded this

• Positive Candida culture, adjusted OR (adjusted for cancer diagnosis)

  no effect, p = 0.168

  1 | Growth (%) | 30 (76.9) | 26 (66.7) | 1.67 (0.61–4.53) | 0.316 | 2.13 (0.73–6.23) | 0.168

  PMID:39651788 · one of two readings recorded this

• Positive Candida culture, adjusted OR (adjusted for cancer diagnosis)

  decreases, p = 0.024

  4 | Growth (%) | 22 (59.5) | 31 (83.8) | 0.28 (0.10–0.85) | 0.024 | 0.27 (0.08–0.84) | 0.024

  PMID:39651788 · one of two readings recorded this

• Positive Candida culture, adjusted OR (adjusted for cancer diagnosis)

  decreases, p = 0.029

  7 | Growth (%) | 16 (44.4) | 26 (72.2) | 0.31 (0.12–0.82) | 0.019 | 0.32 (0.12–0.89) | 0.029

  PMID:39651788 · one of two readings recorded this

• Positive Candida culture, unadjusted OR

  no effect, p = 0.316

  1 | Growth (%) | 30 (76.9) | 26 (66.7) | 1.67 (0.61–4.53) | 0.316 | 2.13 (0.73–6.23) | 0.168

  PMID:39651788 · one of two readings recorded this

• Positive Candida culture, unadjusted OR

  decreases, p = 0.024

  4 | Growth (%) | 22 (59.5) | 31 (83.8) | 0.28 (0.10–0.85) | 0.024 | 0.27 (0.08–0.84) | 0.024

  PMID:39651788 · one of two readings recorded this

• Positive Candida culture, unadjusted OR

  decreases, p = 0.019

  7 | Growth (%) | 16 (44.4) | 26 (72.2) | 0.31 (0.12–0.82) | 0.019 | 0.32 (0.12–0.89) | 0.029

  PMID:39651788 · one of two readings recorded this

• radiation-induced oral mucositis grade 2 or higher incidence by CTCAE version 5.0 at weeks 1, 4 and 7 of chemoradiotherapy (primary), and oral Candida carriage by oral rinse culture with colony-forming units (secondary), fluconazole 100 mg daily versus placebo

  OR 0.47 (95% CI: 0.24–0.90) for arm A (fluconazole) in mixed-effects ordinal logistic regression, p = 0.023

  Not recorded as a finding: this platform holds no node for the endpoint

  In the mixed-effects ordinal logistic regression analysis, patients in Arm A had an OR of 0.47 (95% CI: 0.24–0.90, p = 0.023).

  PMID:39651788 · one of two readings recorded this

• radiation-induced oral mucositis grade, CTCAE v5.0 at weeks 1, 4 and 7 of chemoradiotherapy (primary: incidence of grade 2 or higher); oral Candida carriage by oral-rinse culture and colony-forming units

  mixed-effects ordinal logistic regression, fluconazole arm OR 0.47 (95% CI 0.24-0.90) versus placebo, p = 0.023

  Not recorded as a finding: this platform holds no node for the endpoint

  In the mixed‐effects ordinal logistic regression analysis, patients in Arm A had an OR of 0.47 (95% CI: 0.24–0.90, p = 0.023).

  PMID:39651788 · one of two readings recorded this

• RIOM severity, mixed-effects model, cancer diagnosis

  no effect, p = 0.083

  In contrast, the laryngeal and hypopharyngeal cancer group had an OR of 0.43 (95% CI: 0.17–1.12, p = 0.083)

  PMID:39651788 · one of two readings recorded this

• RIOM severity, mixed-effects model, cancer diagnosis

  increases, p = 0.004

  For cancer diagnosis, patients with oral cavity and oropharyngeal cancers had an OR of 3.21 (95% CI: 1.46–7.04, p = 0.004)

  PMID:39651788 · one of two readings recorded this

• RIOM severity, mixed-effects model, cancer diagnosis

  no effect, p = 0.945

  Patients with other types of cancers had an OR of 1.05 (95% CI: 0.28–3.91, p = 0.945)

  PMID:39651788 · one of two readings recorded this

• RIOM severity, mixed-effects model, time during CCRT

  increases, p = 0.001

  The time during CCRT had an OR of 2.31 (95% CI: 1.89–2.83, p < 0.001)

  PMID:39651788 · one of two readings recorded this

• RIOM severity, mixed-effects ordinal logistic regression, Arm A vs Arm B

  decreases, p = 0.023

  patients in Arm A had an OR of 0.47 (95% CI: 0.24–0.90, p = 0.023)

  PMID:39651788 · one of two readings recorded this

• Unidentified yeast positive cultures

  Unidentified yeast (n) | 12 | 6

  PMID:39651788 · one of two readings recorded this

• Unidentified yeast positive cultures

  Unidentified yeast (n) | 15 | 10

  PMID:39651788 · one of two readings recorded this

• Unidentified yeast positive cultures

  Unidentified yeast (n) | 9 | 6

  PMID:39651788 · one of two readings recorded this

• Weight loss, between-arm difference

  no effect, p = 0.734

  no significant differences in OTT or median weight loss between the two arms (p = 0.697 and p = 0.734, respectively)

  PMID:39651788 · one of two readings recorded this

• Aspergillosis

  no effect, n = 46

  Aspergillosis was observed in 46 patients (38.3%), with 23 patients (38.3%) in each group

  PMID:40152076 · one of two readings recorded this

• Candida colonization at oral cavity, third week

  decreases, p = 0.03

  with statistically significant changes observed in the third week at the oral cavity (p = 0.03)

  PMID:40152076 · one of two readings recorded this

• Candida infections as failure of primary prophylaxis in acute leukemia, fluconazole 150 mg/day versus fluconazole 400 mg/day, both oral

  no effect, p = 0.615

  Not recorded as a finding: the comparison was against another active treatment

  A total of 31 patients (25.8%) developed Candida infections as a failure of primary prophylaxis, with 14 patients (23.3%) in Group 1 and 17 patients (28.3%) in Group 2, showing no significant difference between the groups (p = 0.615).

  PMID:40152076 · one of two readings recorded this

• Candida infections as failure of primary prophylaxis

  no effect, p = 0.615

  A total of 31 patients (25.8%) developed Candida infections as a failure of primary prophylaxis, with 14 patients (23.3%) in Group 1 and 17 patients (28.3%) in Group 2, showing no significant difference between the groups (p = 0.615)

  PMID:40152076 · one of two readings recorded this

• Candidemia

  no effect

  Candidemia | 0 (0) | 0 (0) | 0

  PMID:40152076 · one of two readings recorded this

• Candidemia

  no effect, p = 0.183

  Candidemia | ALL | 0 (0%) | 0 (0%) | 0.183

  PMID:40152076 · one of two readings recorded this

• Candidemia

  no effect

  AML | 0 (0%) | 0 (0%)

  PMID:40152076 · one of two readings recorded this

• Days of prophylaxis

  no effect, p = 0.407

  Days of prophylaxis; mean (range) | 18.3 (3–48) | 19.5 (3–0) | 0.407

  PMID:40152076 · one of two readings recorded this

• Death during prophylactic regimen

  no effect, p = 0.99, n = 5

  During the prophylactic regimen, 5 patients (4.1%) died: 3 patients (5%) from Group 1 and 2 patients (3.3%) from Group 2 (p > 0.99)

  PMID:40152076 · one of two readings recorded this

• Discharge

  no effect, p = 0.509

  Discharge; N (%) | 56 (93.3) | 54 (90.0) | 0.509

  PMID:40152076 · one of two readings recorded this

The whole record — 283 rows